Therapy outcomes showing first-line chemotherapy duration, platinum-free interval, and second-line chemotherapy duration, followed by triplet maintenance therapy.
death
CPS
Patients who are included in the ongoing triplet maintenance trial are marked with arrows; progression and death dates are marked. The 6 months time point since the start of triplet maintenance is marked with a vertical dashed line. HRD Homologous recombination deficiency, PD-L1 CPS Programmed death ligand-1 combined positive score. Source data are provided as a Source Data file.